肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病疗效研究  

Feitai capsule combined with linezolid in the treatment of extensively drug-resistant tuberculosis

作　　者：夏琴 XIA Qin(Department of Pharmacy,Xianyang Central Hospital of Shaanxi Province,Xianyang 712000)

机构地区：[1]陕西省咸阳市中心医院药学部,咸阳712000

出　　处：《陕西中医》2019年第4期469-471,共3页Shaanxi Journal of Traditional Chinese Medicine

摘　　要：目的:探讨肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病患者的临床效果以及不良反应。方法:收集106例广泛性耐药结核病患者,按照数字随机表法分为两组各53例,研究组在利奈唑胺治疗的基础上联合使用肺泰胶囊,对照组仅使用利奈唑胺进行治疗,对比观察两组患者的临床效果和治疗安全性。结果:研究组患者在治疗1、3、6个月后痰菌阴转率分别为67.92%、84.91%、98.11%,均明显高于对照组52.83%、69.81%和75.47%,组间比较差异具有统计学意义(P<0.05);治疗后研究组患者肺部病灶吸收、空洞闭合和临床症状改善情况均明显优于对照组改善情况,改善时间短于对照组改善时间,差异均具有统计学意义(P<0.05);研究组不良事件发生率为16.98%,明显少于对照组32.08%,差异具有统计学意义(P<0.05)。结论:肺泰胶囊联合利奈唑胺治疗广泛性耐药结核病患者能够有效的促进肺部病灶吸收和空洞闭合,加快痰菌转阴,降低不良反应,效果显著。Objective:To investigate the clinical efficacy and adverse reactions of Feitai capsule combined with linezolid in the treatment of extensively drug-resistant tuberculosis. Methods:106 patients with extensively drug-resistant tuberculosis were divided into two groups according to the method of digital random table,53 cases in each group. The clinical effect and safety of treatment. Results :The sputum negative conversion rates of the study group were 67.92%,84.91% and 98.11% respectively after 1,3 and 6 months of treatment,which were significantly higher than those of the control group (52.83%,69.81% and 75.47%). The difference between the two groups was statistically significant ( P <0.05). The incidence of gastrointestinal reaction,liver damage,leukopenia,gout and other adverse reactions in the study group was 16.98%,which was significantly less than that in the control group (32.08%). The difference was statistically significant ( P <0.05). Conclusion: Feitai capsule combined with linezolid in the treatment of extensively drug-resistant tuberculosis patients can effectively promote the absorption of lung lesions and cavity closure,accelerate sputum negative,reduce adverse reactions,the effect is significant,can be widely used.

关 键 词：广泛性耐药结核病 肺泰胶囊 利奈唑胺 不良反应 临床效果 安全性 

分 类 号：R52[医药卫生—内科学]